Genetics of hepatocellular carcinoma.

The completely assembled human genome has made it possible for modern medicine to step into an era rich in genetic information and high-throughput genomic analysis. These novel and readily available genetic resources and analytical tools may be the key to unravel the molecular basis of hepatocellular carcinoma (HCC). Moreover, since an efficient treatment for this disease is lacking, further understanding of the genetic background of HCC will be crucial in order to develop new therapies aimed at selected targets. We report on the current status and recent developments in HCC genetics. Special emphasis is given to the genetics and regulation of major signalling pathways involved in HCC such as p53, Wnt-signalling, TGFbeta, Ras, and Rb pathways. Furthermore, we describe the influence of chromosomal aberrations as well as of DNA methylation. Finally, we report on the rapidly developing field of genomic expression profiling in HCC, mainly by microarray analysis.

[1]  M. Watatani,et al.  Infrequent activation of K-ras, H-ras, and other oncogenes in hepatocellular neoplasms initiated by methyl(acetoxymethyl)nitrosamine, a methylating agent, and promoted by phenobarbital in F344 rats. , 1989, Cancer research.

[2]  H. Lai,et al.  Promoter methylation of the secreted frizzled‐related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma , 2006, Cancer.

[3]  Mark S. Boguski,et al.  Proteins regulating Ras and its relatives , 1993, Nature.

[4]  C. Abbott,et al.  Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. , 2002, The American journal of pathology.

[5]  P. Chambon,et al.  DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor. , 1993, Science.

[6]  C. Harris,et al.  p53: traffic cop at the crossroads of DNA repair and recombination , 2005, Nature Reviews Molecular Cell Biology.

[7]  K. Isselbacher,et al.  p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Giovannini,et al.  Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Dou,et al.  Cellular response to gene expression profiles of different hepatitis C virus core proteins in the Huh-7 cell line with microarray analysis. , 2005, Journal of nanoscience and nanotechnology.

[10]  C. Harris,et al.  p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. , 1996, Carcinogenesis.

[11]  H. Bourne,et al.  Some signal developments , 1990, Nature.

[12]  A. Brehm,et al.  E2F-Rb complexes regulating transcription of genes important for differentiation and development. , 2005, Current opinion in genetics & development.

[13]  M. Chen,et al.  Activation of p53 tumor suppressor by hepatitis C virus core protein. , 1999, Virology.

[14]  L. Wakefield,et al.  Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. , 2002, The Journal of clinical investigation.

[15]  S. Gautam,et al.  Inactivation of TGF-β signaling in hepatocytes results in an increased proliferative response after partial hepatectomy , 2005, Oncogene.

[16]  M. Karin,et al.  AP-1 as a regulator of cell life and death , 2002, Nature Cell Biology.

[17]  R. Treisman,et al.  The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain , 1993, Cell.

[18]  S. Thorgeirsson,et al.  SMAD5 gene expression, rearrangements, copy number, and amplification at fragile site FRA5C in human hepatocellular carcinoma. , 2003, Neoplasia.

[19]  D. Housman,et al.  Rate-limiting steps: The genetics of pediatric cancers , 1991, Cell.

[20]  Y. Hoshida,et al.  Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients. , 2005, World journal of gastroenterology.

[21]  M. Ozturk,et al.  Smad2 and Smad4 gene mutations in hepatocellular carcinoma , 1999, Oncogene.

[22]  R. Metcalf,et al.  p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. , 1993, Carcinogenesis.

[23]  C. Der,et al.  Guanine nucleotide exchange factors: Activators of the Ras superfamily of proteins , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[24]  A. Barbin.  Formation of DNA etheno adducts in rodents and humans and their role in carcinogenesis. , 1998, Acta biochimica Polonica.

[25]  M. Matsuda,et al.  Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis , 2003, International journal of cancer.

[26]  S. Hirohashi,et al.  Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. , 1994, Cancer letters.

[27]  S. Hirohashi,et al.  p53 gene mutation spectrum in hepatocellular carcinoma. , 1992, Cancer research.

[28]  D. Amadori,et al.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Dirk Inzé,et al.  Plant cell cycle transitions. , 2003, Current opinion in plant biology.

[30]  Jeanne M Clark,et al.  The Epidemiology of Nonalcoholic Fatty Liver Disease in Adults , 2006, Journal of clinical gastroenterology.

[31]  Y. Kaziro,et al.  Ras in signal transduction. , 1992, Seminars in cancer biology.

[32]  V. Rotter,et al.  Introduction: p53 – the first twenty years , 1999, Cellular and Molecular Life Sciences CMLS.

[33]  T. Nakamura,et al.  Relation of type II transforming growth factor-beta receptor to hepatic fibrosis and hepatocellular carcinoma. , 2001, International journal of oncology.

[34]  B. Slagle,et al.  p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. , 1992, Cancer research.

[35]  Jie-quan Yang,et al.  Differentially expressed genes between solitary large hepatocellular carcinoma and nodular hepatocellular carcinoma. , 2004, World journal of gastroenterology.

[36]  Y. Nakanishi,et al.  Codon 64 of K-ras gene mutation pattern in hepatocellular carcinomas induced by bleomycin and 1-nitropyrene in A/J mice. , 2003, Teratogenesis, carcinogenesis, and mutagenesis.

[37]  G. Wogan,et al.  Activation of the c-Ki-ras oncogene in aflatoxin B1-induced hepatocellular carcinoma and adenoma in the rat: detection by denaturing gradient gel electrophoresis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Dannenberg,et al.  The retinoblastoma gene family in cell cycle regulation and suppression of tumorigenesis. , 2006, Results and problems in cell differentiation.

[39]  J. Jobst,et al.  Genotype–phenotype relationships in hepatocellular tumors from mice and man , 2005, Hepatology.

[40]  Y. Jeng,et al.  Expression of mutant nuclear β‐catenin correlates with non‐invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis , 2001, The Journal of pathology.

[41]  P. Schirmacher,et al.  Hepatocellular expression of a dominant-negative mutant TGF-β type II receptor accelerates chemically induced hepatocarcinogenesis , 2001, Oncogene.

[42]  K. Chayama,et al.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis , 1993, Hepatology.

[43]  A. Buchmann,et al.  p53 Mutations in human hepatocellular carcinomas from Germany. , 1992, Cancer research.

[44]  R. Jordan,et al.  Molecular viral oncology of hepatocellular carcinoma , 2003, Oncogene.

[45]  S. Maeda,et al.  p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. , 1994, Cancer research.

[46]  I. Kung,et al.  Angiosarcoma and hepatocellular carcinoma in vinyl chloride workers , 1983, Histopathology.

[47]  L. Wakefield,et al.  Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency , 1998, Nature Medicine.

[48]  C. Harris,et al.  Hepatitis B virus X protein inhibits nucleotide excision repair , 1999, International journal of cancer.

[49]  M. Steiner,et al.  Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. , 1992, Molecular endocrinology.

[50]  S. Thorgeirsson,et al.  Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. , 2004, Gastroenterology.

[51]  K. Jones,et al.  Wnt signaling: is the party in the nucleus? , 2006, Genes & development.

[52]  M. Emi,et al.  DNA alterations during multi-step development of human hepatocellular carcinomas revealed by laser capture microdissection. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[53]  David I. Smith,et al.  Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas , 2002, Oncogene.

[54]  C. S. Lee,et al.  Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. , 1993, Oncogene.

[55]  K. Koike,et al.  Activated N-ras gene was found in human hepatoma tissue but only in a small fraction of the tumor cells. , 1989, Oncogene.

[56]  K. Shimotohno,et al.  Hepatitis C Virus Core Protein Inhibits Fas- and Tumor Necrosis Factor Alpha-Mediated Apoptosis via NF-κB Activation , 1999, Journal of Virology.

[57]  Tim Perera,et al.  The Wnt-dependent signaling pathways as target in oncology drug discovery , 2006, Investigational New Drugs.

[58]  R. Jirtle,et al.  Transforming growth factor-beta receptors type I, II and III in phenobarbital-promoted rat liver tumors. , 1994, Carcinogenesis.

[59]  S. Ye,et al.  Apoptosis of human BEL-7402 hepatocellular carcinoma cells released by antisense H-ras DNA-in vitro and in vivo studies , 2005, Journal of Cancer Research and Clinical Oncology.

[60]  X. Wang,et al.  Cancer‐associated molecular signature in the tissue samples of patients with cirrhosis , 2004, Hepatology.

[61]  Varda Rotter,et al.  Nitric oxide-induced cellular stress and p53 activation in chronic inflammation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[62]  C. Harris,et al.  Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Y. Ahn,et al.  Comparative analysis of expression profiling of early-stage carcinogenesis using nodule-in-nodule-type hepatocellular carcinoma , 2006, European journal of gastroenterology & hepatology.

[64]  Hiroyoshi Taniguchi,et al.  Relevance network between chemosensitivity and transcriptome in human hepatoma cells. , 2003, Molecular cancer therapeutics.

[65]  P. Cerutti,et al.  Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. , 1994, Cancer research.

[66]  S. Hirohashi,et al.  Low Incidence of Point Mutation of c‐Ki‐ras and N‐ras Oncogenes in Human Hepatocellular Carcinoma , 1989, Japanese journal of cancer research : Gann.

[67]  O. Yokosuka,et al.  Cell Growth Inhibition and Gene Expression Induced by the Histone Deacetylase Inhibitor, Trichostatin A, on Human Hepatoma Cells , 2004, Oncology.

[68]  Y. N. Park,et al.  Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-beta. , 2004, Hepato-gastroenterology.

[69]  M. Honda,et al.  Differential gene expression between chronic hepatitis B and C hepatic lesion. , 2001, Gastroenterology.

[70]  T. Hanai,et al.  Specific Gene-Expression Profiles of Noncancerous Liver Tissue Predict the Risk for Multicentric Occurrence of Hepatocellular Carcinoma in Hepatitis C Virus–Positive Patients , 2006, Annals of Surgical Oncology.

[71]  S. D. L. Monte,et al.  Oncogenic role of the frizzled-7/β-catenin pathway in hepatocellular carcinoma , 2005 .

[72]  R. Derynck,et al.  TGF-β signaling in cancer – a double-edged sword , 2001 .

[73]  Tatsushi Yoshida,et al.  Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. , 2005, Biochimica et biophysica acta.

[74]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[75]  J. Dou,et al.  Preliminary analysis of gene expression profiles in HepG2 cell line induced by different genotype core proteins of HCV. , 2006, Cellular & molecular immunology.

[76]  S. Tanaka,et al.  Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. , 1993, Cancer research.

[77]  S. Fan,et al.  HDPR1, a novel inhibitor of the WNT/β-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing , 2005, Oncogene.

[78]  W. Bursch,et al.  Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[79]  H. Sriplung,et al.  Epidemiology of liver cancer: an overview. , 2004, Asian Pacific journal of cancer prevention : APJCP.

[80]  Jack A. Taylor,et al.  CTNNB1 mutations and β‐catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1 † , 2001, Molecular carcinogenesis.

[81]  Sarah B Tegen,et al.  The Transforming Activity of Ski and SnoN Is Dependent on Their Ability to Repress the Activity of Smad Proteins* , 2003, Journal of Biological Chemistry.

[82]  W. Baek,et al.  5-Aza-2'-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines. , 2000, Cancer letters.

[83]  A. Tannapfel,et al.  Frequent k- ras -2 mutations and p16INK4Amethylation in hepatocellular carcinomas in workers exposed to vinyl chloride , 2001, British Journal of Cancer.

[84]  Mark L. Johnson,et al.  Diseases of Wnt signaling , 2007, Reviews in Endocrine and Metabolic Disorders.

[85]  Y. Jeng,et al.  Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. , 2000, The American journal of pathology.

[86]  L. Wakefield,et al.  TGF-β signaling: positive and negative effects on tumorigenesis , 2002 .

[87]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[88]  P. Warne,et al.  Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro , 1993, Nature.

[89]  Jingde Zhu,et al.  Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis , 2003, Cell Research.

[90]  A. Tannapfel,et al.  High prevalence of K-ras-2 mutations in hepatocellular carcinomas in workers exposed to vinyl chloride , 2001, International archives of occupational and environmental health.

[91]  Yusuke Nakamura,et al.  AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 , 2000, Nature Genetics.

[92]  N. Iizuka,et al.  Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. , 2002, Cancer research.

[93]  C. Harris,et al.  Geographic variation of p53 mutational profile in nonmalignant human liver. , 1994, Science.

[94]  M. Uribe,et al.  Hepatocellular carcinoma. An overview. , 2006, Annals of hepatology.

[95]  S. Elledge,et al.  Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1 , 1993, Nature.

[96]  S. Ye,et al.  Modulation of apoptosis, tumorigenesity and metastatic potential with antisense H-ras oligodeoxynucleotides in a high metastatic tumor model of hepatoma: LCI-D20. , 2000, Hepato-gastroenterology.

[97]  K. Furge,et al.  Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. , 2004, International journal of oncology.

[98]  C. Der,et al.  The Ras branch of small GTPases: Ras family members don't fall far from the tree. , 2000, Current opinion in cell biology.

[99]  J. Bartek,et al.  Deregulation of the G1/S‐phase control in human testicular germ cell tumours , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[100]  J. Tsai,et al.  Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. , 1997, British Journal of Cancer.

[101]  G. -. Lee,et al.  Low frequency of ras activation in 2-acetylaminofluorene- and 3'-methyl-4-(dimethylamino)azobenzene-induced rat hepatocellular carcinomas. , 1991, Cancer letters.

[102]  Wei Jiang,et al.  Wnt/beta-catenin signaling pathway as a novel cancer drug target. , 2004, Current cancer drug targets.

[103]  C. Challen,et al.  Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. , 1992, Journal of hepatology.

[104]  S. Thorgeirsson,et al.  Acceleration of c-myc-induced hepatocarcinogenesis by Co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption. , 1999, The American journal of pathology.

[105]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[106]  Wen-Hwa Lee,et al.  SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene , 1988, Cell.

[107]  A. Wolfman,et al.  The 3Rs of life: Ras, Raf and growth regulation. , 1994, Trends in genetics : TIG.

[108]  H. Iishi,et al.  Ha‐ras mutations in N‐nitrosomorpholine‐induced lesions and inhibition of hepatocarcinogenesis by antisense sequences in rat liver , 1997, International journal of cancer.

[109]  A. Tannapfel,et al.  p53 mutation pattern in hepatocellular carcinoma in workers exposed to vinyl chloride , 2000, Cancer.

[110]  K. Matsuzaki,et al.  Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. , 2000, Cancer research.

[111]  S. Hirohashi,et al.  Inactivation of p16INK4 in hepatocellular carcinoma , 1996, Hepatology.

[112]  M. Wigler,et al.  Complex formation between RAS and RAF and other protein kinases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[113]  A. Bosserhoff,et al.  Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. , 2006, Oncology reports.

[114]  J. Shimazaki,et al.  Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[115]  John N Weinstein,et al.  The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. , 2005, Cancer research.

[116]  J. Wands,et al.  Hepatitis C virus core protein stimulates hepatocyte growth: Correlation with upregulation of wnt‐1 expression , 2005, Hepatology.

[117]  Yan-Hwa Wu Lee,et al.  Hepatitis C Virus Core Protein Enhances NF-κB Signal Pathway Triggering by Lymphotoxin-β Receptor Ligand and Tumor Necrosis Factor Alpha , 1999, Journal of Virology.

[118]  A. Nonomura,et al.  Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma. , 1987, The American journal of gastroenterology.

[119]  M. Matsuda,et al.  β-Catenin Mutations Are Frequent in Human Hepatocellular Carcinomas Associated with Hepatitis C Virus Infection , 1999 .

[120]  Won Young Tak,et al.  Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. , 2002, Molecules and cells.

[121]  J. Jang,et al.  Cyclin D1 overexpression in hepatocellular carcinoma. , 2001, Liver.

[122]  W. Lau,et al.  Tumor‐Derived Epigenetic Changes in the Plasma and Serum of Liver Cancer Patients: Implications for Cancer Detection and Monitoring , 2000, Annals of the New York Academy of Sciences.

[123]  P. Cerutti,et al.  Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[124]  D. Lowy,et al.  The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. , 1990, The EMBO journal.

[125]  P. Pineau,et al.  Close correlation between β-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas , 1999, Oncogene.

[126]  H. Friess,et al.  Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. , 1999, American journal of surgery.

[127]  K. Meyer,et al.  Transcriptional Repression of p53 Promoter by Hepatitis C Virus Core Protein* , 1997, The Journal of Biological Chemistry.

[128]  S. Thorgeirsson,et al.  Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. , 2001, Cancer research.

[129]  S. Wakana,et al.  Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. , 1996, Carcinogenesis.

[130]  J. Squire,et al.  Transcriptional profiling identifies gene expression changes associated with IFN-alpha tolerance in hepatitis C-related hepatocellular carcinoma cells. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[131]  Allan Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[132]  X. Wang,et al.  TP53 and liver carcinogenesis , 2003, Human mutation.

[133]  P. Schirmacher,et al.  Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade – results of an explorative CGH meta-analysis , 2005, British Journal of Cancer.

[134]  N. Fausto.  Hepatocyte apoptosis: is transforming growth factor-B1 the kiss of death? , 1993, Hepatology.

[135]  J. Tsai,et al.  Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma. , 1997, Medicine.

[136]  Y. Matsuzawa,et al.  Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. , 1995, Cancer letters.

[137]  Seok-Geun Lee,et al.  Transcriptional repression of the human p53 gene by hepatitis B viral X protein , 2000, Oncogene.

[138]  E. Bergsland.  Molecular mechanisms underlying the development of hepatocellular carcinoma. , 2001, Seminars in oncology.

[139]  A. Llombart‐Bosch,et al.  K-ras Gene Mutations in Liver Carcinomas from a Mediterranean Area of Spain , 2000, International journal of surgical pathology.

[140]  F. Kelleher,et al.  Common critical pathways in embryogenesis and cancer , 2006, Acta oncologica.

[141]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[142]  K. Jaskiewicz,et al.  Differential expression of transforming growth factor alpha, adhesions molecules and integrins in primary, metastatic liver tumors and in liver cirrhosis. , 1995, Anticancer research.

[143]  N. Iizuka,et al.  MECHANISMS OF DISEASE Mechanisms of disease , 2022 .

[144]  C. Harris,et al.  Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[145]  K. McGlynn,et al.  Epidemiology and natural history of hepatocellular carcinoma. , 2005, Best practice & research. Clinical gastroenterology.

[146]  D. Morrison,et al.  The complexity of Raf-1 regulation. , 1997, Current opinion in cell biology.

[147]  M. Weber,et al.  Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. , 1993, Science.

[148]  A. Thor,et al.  ras oncogene p21 expression in hepatocellular carcinoma. , 1989, Journal of experimental pathology.

[149]  C. Harris,et al.  p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. , 1994, Carcinogenesis.

[150]  B. Trink,et al.  p53 associates with and targets ΔNp63 into a protein degradation pathway , 2001 .

[151]  Jonathan A. Cooper,et al.  Mammalian Ras interacts directly with the serine/threonine kinase raf , 1993, Cell.

[152]  T. Kurihara,et al.  Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. , 2004, International journal of oncology.

[153]  R. Britton.  Metal-Induced Hepatotoxicity , 1996, Seminars in liver disease.

[154]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[155]  X. Wang,et al.  The Molecular Signature of Metastases of Human Hepatocellular Carcinoma , 2005, Oncology.

[156]  P. Seth,et al.  Targeting TGF beta signaling for cancer therapy , 2005, Cancer biology & therapy.

[157]  Miran Kim,et al.  Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. , 2004, Gastroenterology.

[158]  Rei Takahashi,et al.  Disruption of the p16/Cyclin D1/Retinoblastoma Protein Pathway in the Majority of Human Hepatocellular Carcinomas , 2001, Oncology.

[159]  J. Wands,et al.  p53 mutation in hepatocellular carcinoma after aflatoxin exposure , 1991, The Lancet.

[160]  M. Lai,et al.  Hepatitis C Virus Core Protein Binds to the Cytoplasmic Domain of Tumor Necrosis Factor (TNF) Receptor 1 and Enhances TNF-Induced Apoptosis , 1998, Journal of Virology.

[161]  C. Der,et al.  Differential antagonism of Ras biological activity by catalytic and Src homology domains of Ras GTPase activation protein. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[162]  Karl Münger,et al.  Human papillomavirus immortalization and transformation functions. , 2002, Virus research.

[163]  A. Barbin.  Etheno-adduct-forming chemicals: from mutagenicity testing to tumor mutation spectra. , 2000, Mutation research.

[164]  W. Yeo,et al.  High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[165]  H. Popper,et al.  Early Hepatic Histologic Alterations Among Chemical (Vinyl Monomer) Workers , 1984, Hepatology.

[166]  J. Jett,et al.  Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[167]  S. Fan,et al.  β‐catenin mutation and overexpression in hepatocellular carcinoma , 2001 .

[168]  A. Capovilla,et al.  Putative role of hepatitis B virus X protein in hepatocarcinogenesis: Effects on apoptosis, DNA repair, mitogen‐activated protein kinase and JAK/STAT pathways , 2000, Journal of gastroenterology and hepatology.

[169]  J. Bartek,et al.  Deregulation of the RB pathway in human testicular germ cell tumours , 2003, The Journal of pathology.

[170]  N. Iizuka,et al.  Gene expression profile linked to p53 status in hepatitis C virus‐related hepatocellular carcinoma , 2003, FEBS letters.

[171]  Carlos L. Arteaga,et al.  Targeting the TGFβ signaling network in human neoplasia , 2003 .

[172]  E.K. Teo,et al.  Hepatocellular Carcinoma: An Asian Perspective , 2002, Digestive Diseases.

[173]  C. Harris,et al.  p53: 25 years after its discovery. , 2004, Trends in pharmacological sciences.

[174]  T. Kouzarides,et al.  Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein. , 1994, The EMBO journal.

[175]  H. Lee,et al.  Transforming growth factor‐β1 as a useful serologic marker of small hepatocellular carcinoma , 2002 .

[176]  M. Buendia,et al.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.